Portal:Treatments/Selected article/3: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Notjusttired (talk | contribs) (update/ finish) |
Notjusttired (talk | contribs) m (format) |
||
Line 2: | Line 2: | ||
'''Ampligen.jpg®︎''' (generic name '''rintatolimod''') is a drug with immunomodulatory and [[antiviral]] properties that is approved for [[Severe and very severe ME|severe ME/CFS]] in [[Argentina]]. Although Ampligen is not FDA-approved for ME/CFS it is available under early access or compassionate care programs in the [[United States]], EU countries, and Turkey. | '''Ampligen.jpg®︎''' (generic name '''rintatolimod''') is a drug with immunomodulatory and [[antiviral]] properties that is approved for [[Severe and very severe ME|severe ME/CFS]] in [[Argentina]]. Although Ampligen is not FDA-approved for ME/CFS it is available under early access or compassionate care programs in the [[United States]], EU countries, and Turkey. | ||
Ampligen has been shown to raise the reduced [[natural killer cell]] (NK) function found in ME/CFS patients | Ampligen has been shown to raise the reduced [[natural killer cell]] (NK) function found in ME/CFS patients ('''[[Ampligen|more]]...''') |
Revision as of 18:50, July 20, 2021
Ampligen.jpg®︎ (generic name rintatolimod) is a drug with immunomodulatory and antiviral properties that is approved for severe ME/CFS in Argentina. Although Ampligen is not FDA-approved for ME/CFS it is available under early access or compassionate care programs in the United States, EU countries, and Turkey.
Ampligen has been shown to raise the reduced natural killer cell (NK) function found in ME/CFS patients (more...)